{
  "asset": {
    "name": "KT-621",
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "target": "STAT6",
    "mechanism": "First-in-class oral STAT6 degrader",
    "modality": "Oral small molecule degrader",
    "partner": null
  },
  "clinical_development": {
    "current_stage": "Phase 2",
    "indications_in_development": [
      "Atopic Dermatitis",
      "Asthma",
      "COPD",
      "EoE",
      "CRSwNP",
      "CSU",
      "PN",
      "BP"
    ]
  },
  "trials": [
    {
      "name": "BROADEN2",
      "nct_id": null,
      "phase": "Phase 2b",
      "status": "Ongoing",
      "indication": "Moderate to Severe Atopic Dermatitis",
      "design": "Randomized, double-blind, placebo-controlled, parallel-group, multicenter dose-ranging",
      "population": "Adult & Adolescent Moderate to Severe AD Patients Ages 12-75",
      "arms": [
        {
          "name": "Three KT-621 doses + placebo",
          "dose": "1:1:1:1 randomization",
          "n": null
        }
      ],
      "primary_endpoint": "Percent change from baseline in EASI score at week 16",
      "endpoints": [],
      "safety": null,
      "_source_pages": [
        19
      ]
    },
    {
      "name": "BREADTH",
      "nct_id": null,
      "phase": "Phase 2b",
      "status": "Ongoing",
      "indication": "Moderate to Severe Eosinophilic Asthma",
      "design": "Randomized, double-blind, placebo-controlled, parallel-group, multicenter dose-ranging",
      "population": "Adult, Moderate to Severe Eosinophilic Asthma Patients",
      "arms": [
        {
          "name": "Three KT-621 doses + placebo",
          "dose": "1:1:1:1 randomization",
          "n": null
        }
      ],
      "primary_endpoint": "Percent change from baseline in pre-bronchodilator FEV1 at week 12",
      "endpoints": [],
      "safety": null,
      "_source_pages": [
        20
      ]
    },
    {
      "name": "BroADen Phase 1b",
      "nct_id": null,
      "phase": "Phase 1b",
      "status": "Completed",
      "indication": "Moderate to Severe Atopic Dermatitis",
      "design": "Single arm, open label",
      "population": "Adult, moderate to severe AD patients",
      "arms": [
        {
          "name": "100 mg cohort",
          "dose": "100 mg QD",
          "n": 10
        },
        {
          "name": "200 mg cohort",
          "dose": "200 mg QD",
          "n": 12
        }
      ],
      "primary_endpoint": "Safety, pharmacokinetics, STAT6 degradation, Type 2 biomarkers, clinical activity",
      "endpoints": [
        {
          "endpoint": "STAT6 degradation in blood",
          "result": "98%",
          "timepoint": "Throughout treatment",
          "p_value": null,
          "vs_comparator": null
        },
        {
          "endpoint": "STAT6 degradation in skin",
          "result": "94%",
          "timepoint": "Day 29",
          "p_value": null,
          "vs_comparator": null
        },
        {
          "endpoint": "Mean % change in EASI",
          "result": "-63%",
          "timepoint": "Day 29",
          "p_value": null,
          "vs_comparator": "Dupilumab -52% at D28"
        },
        {
          "endpoint": "EASI-50",
          "result": "76%",
          "timepoint": "Day 29",
          "p_value": null,
          "vs_comparator": "Dupilumab 57% at D28"
        },
        {
          "endpoint": "EASI-75",
          "result": "29%",
          "timepoint": "Day 29",
          "p_value": null,
          "vs_comparator": "Dupilumab 28% at D28"
        },
        {
          "endpoint": "TARC reduction",
          "result": "74%",
          "timepoint": "Day 29",
          "p_value": null,
          "vs_comparator": "Dupilumab 74%"
        },
        {
          "endpoint": "Eotaxin-3 reduction",
          "result": "73%",
          "timepoint": "Day 29",
          "p_value": null,
          "vs_comparator": "Dupilumab 51% (in Asthma)"
        }
      ],
      "safety": "Well-tolerated with favorable safety profile. No SAEs or Severe AEs. No dose-dependent pattern in TEAEs. No related TEAEs leading to discontinuation.",
      "_source_pages": [
        24,
        25,
        26,
        28,
        33,
        34
      ]
    }
  ],
  "investment_thesis": [],
  "key_risks": [
    "Risk that cross-trial comparisons may not be reliable as no head-to-head trials have been conducted comparing KT-621 to dupilumab"
  ],
  "upcoming_catalysts": [
    {
      "event": "BROADEN2 Phase 2b AD study data",
      "timing": "By mid-2027"
    },
    {
      "event": "BREADTH Phase 2b asthma trial data",
      "timing": "Late-2027"
    }
  ],
  "_source_pages": [
    11,
    13,
    15
  ],
  "_last_extracted": "2026-02-04T13:13:42.034335"
}